09-20-Daily AI News Daily

Today’s Summary 

Insilico's AI-designed drug makes patients' blood protein profiles three years younger—this isn't just about treating lung disease.
Scientists found that blocking an immune switch leaves senescent cells with nowhere to hide, and declining liver lactate processing capacity may be the real culprit behind muscle loss in older adults.
Biological age clocks are moving from labs to clinics—AI + anti-aging is about to explode.

⚡ Quick Navigation

💡 Tip: Want to try GPT, Claude, Gemini, Codex, Cursor, Grok and other tools mentioned in this article, but don’t want to deal with overseas payments, registration, quotas and tutorials? Head to Aivora to choose official accounts, mirrors, Cursor plans or relay entries by scenario—self-service ordering on the official website, instant card and key delivery.

Today’s AI Life Sciences News

👀 In One Sentence

A lung fibrosis drug made blood protein profiles three years younger—this might be more than just treating disease.

🔑 3 Key Terms

#AIDrugDiscovery #BiologicalAge #Proteomics

🔥 Top 10 Headlines

1. AI-Designed Lung Fibrosis Drug Reverses Biological Age by Three Years

People used to think drugs just treat diseases, but now AI-designed drugs might make you a few years younger as a side effect. Insilico’s rentosertib, developed using their AI platform, not only improved lung function in pulmonary fibrosis patients during clinical trials—six different protein clocks also detected that patients’ blood protein profiles became younger. Patients taking the 60mg dose showed an average biological age reduction of about three years after four weeks. This doesn’t mean patients literally “reversed aging,” but their blood protein composition became more like that of younger people. Interestingly, these changes didn’t perfectly sync with lung function improvements, suggesting the drug might genuinely be affecting aging processes more broadly. Of course, fibrosis, metabolism, and aging are all intertwined anyway, so whether this drug specifically treats lung disease or has broader anti-aging effects still needs more research.

Image

2. Evipedia Launches Grok Bot AI Assistant: Your Personal Longevity Health Advisor

Want to know if a supplement or therapy actually works? Forever Healthy Foundation transformed SpaceX’s Grok AI into Evipedia Grok Bot, specifically serving the longevity community. This AI assistant doesn’t just chat—its answers are based on 770+ continuously updated evidence reviews, with each conclusion labeled as high, medium, or low grade. If there’s clinical evidence, it says so; if not, it straight-up says “insufficient research currently.” Even better, it actively flags financial conflicts of interest—if a study was pharma-sponsored, it’ll tell you. Unlike vague market answers like “may be effective” or “might improve,” this bot will tell you: “This intervention shows moderate evidence in human trials, but long-term safety data is missing.” Completely free, and developer-friendly with an API for integration.

Image

3. Midlife Growth Hormone Suppression Extends Mouse Lifespan by Nearly 10%

Suppressing growth hormone metabolism extends mouse lifespan—this has been studied for decades. Previous experiments all started interventions from birth, but now someone tried starting during a “midlife crisis”—knocking out growth hormone receptor genes in 12-month-old mice (equivalent to human middle age). Result? Male mice still had extended lifespans, though not as dramatic as lifelong intervention, still nearly 10%. Female mice showed weaker effects. Interestingly, these mice had better insulin sensitivity, preserved neuromuscular function and bone microstructure, but increased body fat. Humans with Laron syndrome (born with deficient growth hormone receptor function) have lower rates of certain diseases but no significant lifespan extension, so this path might be less useful for humans.

4. The Secret of Immortal Hydra: Never-Ending Telomerase Expression

Most animals age, but a few hydra species don’t—they don’t age in normal environments, and mortality rates don’t increase over time. Researchers this time focused on telomerase in hydra. Telomerase is a “life-extension enzyme” that can lengthen telomeres at chromosome ends, preventing cells from dying due to replication. Human somatic cells basically don’t express telomerase (which is why we age), only stem cells, germ cells, and cancer cells do in large amounts. Hydra are different—they’re basically walking clusters of stem cells, and any part of their body can regenerate. Research found that hydra’s telomerase catalytic subunit (hyTERT) continuously expresses in high-proliferation regions, remaining stable during both budding reproduction and regeneration. Hydra’s “immortality” probably relies on this trick. Of course, whether humans can learn anything is unclear—after all, our body structure is far more complex.

5. Lilly’s GIP/GLP-1 Dual Agonist Shows Early Efficacy in Mental and Addiction Disorders

Weight-loss wonder drug tirzepatide made Lilly a fortune, now they’re taking brenipatide with the same mechanism and targeting mental illness and addiction disorders. This time it’s not weight loss—it’s “quit drinking” and “anti-depression.” Phase I trials showed brenipatide has a half-life of 9-12 days, supporting once-weekly dosing, with better GI tolerability than existing GLP-1 drugs. Lilly skipped Phase II and launched two Phase III trials: one for major depressive disorder (MDD), another for alcohol use disorder (AUD). Depression affects 322 million globally, alcoholism 400 million—these two indications represent huge markets. More critically, existing AUD drugs assume patients aim for “complete abstinence,” while brenipatide focuses on “changing drinking patterns”—for those who can’t achieve complete abstinence, this might be more realistic. Lilly is also testing it for bipolar disorder, schizophrenia, tobacco and opioid addiction.

6. One Immune Switch May Drive Whole-Body Aging

Aging may partly result from immune cells “slacking off”—they stop clearing damaged, inflammation-producing cells. Researchers blocked a receptor called PD-L2 in mice, and immune clearance function was restored, inflammation decreased, organs, muscles and memory stayed remarkably young. PD-L2 is originally part of an immune checkpoint, used to prevent the immune system from attacking normal cells. But senescent cells also use it as a “shield” to evade immune pursuit. Once this switch is turned off, senescent cells can’t hide anymore. This study suggests targeting PD-L2 might be a new strategy for clearing senescent cells—adding another path beyond existing senolytics. However, immune checkpoints themselves are important, and systemic inhibition might trigger autoimmune issues, so the future challenge is how to precisely target senescent cells.

7. Impaired Liver and Muscle Lactate Metabolism May Be Main Cause of Sarcopenia

Sarcopenia—severe loss of muscle mass and strength in older adults—has always had unclear causes. Some say it’s muscle stem cell failure, others say inflammation or hormonal changes. Now there’s a new explanation: maybe it’s lactate metabolism problems. Research found that aged mice have reduced liver lactate processing capacity, causing lactate accumulation in skeletal muscle, resulting in intracellular acidification (lactic acidosis), which then damages muscle function. More interestingly, activating hypoxia-inducible factor (HIF) or specifically activating HIF1α in the liver can improve lactate tolerance in aged mice, reduce muscle acidosis, and alleviate sarcopenia. This discovery pulls the liver into sarcopenia’s causal chain—aging isn’t a single-organ issue, but multi-organ coordinated dysfunction. Future treatments might not just target muscles, but also restore liver metabolic capacity.

8. Telomeres and Lifespan: Calorie Restriction Slows DNA Damage Accumulation

Calorie restriction (CR) extending lifespan has been studied in animals for decades, but how exactly does it work? Researchers found CR slows the accumulation rate of DNA mutations in multiple mouse tissues—including substitution mutations (one DNA letter changing to another) and insertion/deletion mutations (adding or losing DNA letters). Interestingly, liver cell mutation reduction was most significant, and CR’s protective effect was strongest in “inactive regions” of the genome (regions without genes or unused genes). Why? Probably because active regions already frequently repair DNA damage, so extra CR benefits aren’t large. This study first confirmed CR’s impact on mutational burden at the whole-genome level. However, CR simultaneously improves cell function, metabolism, inflammation and a host of other things, so exactly how much DNA damage reduction contributes to lifespan extension is still unclear.

9. Transformation of Vascular Smooth Muscle into Macrophages in Atherosclerotic Plaques

Atherosclerosis is the number one killer—plaque rupture causes heart attacks or strokes. Plaques are essentially macrophage “graveyards”—macrophages are attracted to plaques, try to repair them, end up killed by the toxic environment, and themselves become part of the plaque. More absurdly, vascular smooth muscle cells (VSMCs) around vessels aren’t content either—they transform into macrophage-like cells, further accelerating plaque growth—almost like cancer self-proliferation. Researchers used single-cell omics and lineage tracing technology to reveal VSMC heterogeneity and clonal expansion, finding they transform from contractile states into synthetic, macrophage-like, foam cell-like and fibroblast-like states. Targeting VSMC plasticity might be a new direction for treating atherosclerosis—such as using phenotype-specific regulation, immunotherapy, nanomedicines or senotherapeutics.

10. Reprogramming Glia into Neurons Becomes Much Less Effective with Age

Reprogramming brain glial cells into neurons can replace neurons lost to neurodegenerative diseases—this is a hot regenerative medicine direction. But most studies used young mice—what about aged mice? Effectiveness drops significantly. Researchers used the retina for experiments (because the retina is part of the central nervous system but easier to study) and found aged Müller glia’s neurogenic capacity significantly declined. Single-cell transcriptomics showed aged glia couldn’t activate progenitor programs, instead entering reactive and inflammatory states. Meanwhile, aged retinas also had more severe neuroimmune responses to injury. Using dexamethasone for immune modulation partially restored neurogenesis. This suggests aging sets both “intrinsic barriers” and “microenvironment barriers” for glial reprogramming—future treatments might need to simultaneously address inflammation and glia’s own state.

📌 Worth Noting

[Product]

[Research]

[Other]

📎 Today’s Quotable Points

1. AI-Designed Drug Rentosertib Reduces Biological Age Markers

  • Factual Conclusion: Insilico’s AI-designed drug rentosertib reduced predicted biological age detected by 6 protein clocks in idiopathic pulmonary fibrosis patients during a 12-week clinical trial, with the 60mg single-dose group averaging approximately 3 years reduction at week 4.
  • Original Source: Lung Fibrosis Drug Lowers Biological Age Estimates
  • Evidence Boundaries: This is a 12-week, 71-participant (42 analyzed) Phase 2a randomized controlled trial. Biological age reduction is based on blood protein profile changes, not actual lifespan or all-cause mortality data. Since fibrosis, metabolism and aging mechanisms are highly intertwined, it cannot currently be determined whether the drug has broad anti-aging effects beyond fibrosis treatment. Lung function improvement and biological age changes were not perfectly correlated, suggesting possible broader biological effects, but longer-term, larger-scale studies are needed for validation.

2. Blocking PD-L2 Restores Immune System’s Ability to Clear Senescent Cells

  • Factual Conclusion: Research found senescent cells express PD-L2 protein to evade immune clearance; knocking out or blocking PD-L2 in mice reduced senescent cell accumulation and improved insulin sensitivity and grip strength.
  • Original Source: One immune switch may help drive aging across the body
  • Evidence Boundaries: This is a mouse model study, not yet validated in humans. PD-L2 is an immune checkpoint protein; systemic inhibition might trigger autoimmune risks similar to checkpoint inhibitor side effects in cancer immunotherapy. The study didn’t clarify long-term effects of PD-L2 blockade on normal tissue function, nor determine optimal targeting strategy (systemic vs. local). Whether human senescent cells use PD-L2 the same way and the therapeutic window of this strategy still require clinical research.

3. Declining Liver Lactate Metabolism May Be Root Cause of Sarcopenia

  • Factual Conclusion: Research found aged mice have reduced liver lactate processing capacity, causing skeletal muscle lactate accumulation and intracellular acidification; pharmacological or liver-specific activation of hypoxia-inducible factor (HIF1α) improved lactate tolerance and alleviated sarcopenia.
  • Original Source: Impaired Lactate Metabolism in Liver and Muscle as an Important Cause of Sarcopenia
  • Evidence Boundaries: This is a mouse model study focused on the liver-muscle lactate metabolism axis. Human sarcopenia has complex causes involving muscle stem cell function, inflammation, hormonal changes and many factors; lactate metabolism disorder’s relative importance is unclear. HIF1α activation’s systemic effects (such as impacts on cardiovascular system, cancer risk) weren’t fully assessed in the study. Human studies are needed to confirm causal relationship between liver lactate processing capacity and sarcopenia, and the safety and efficacy of HIF activation.

🔮 AI Life Sciences Trend Predictions

AlphaFold/Protein Design Tools Enter Clinical Application Boom Period

  • Predicted Timeline: Q4 2026
  • Prediction Probability: 70%
  • Prediction Basis: Today’s news shows AI-designed lung fibrosis drug rentosertib has completed Phase 2a clinical trial , demonstrating complete pathway from AI drug design to clinic. Combined with ongoing pipelines from AI drug companies like Insilico and Recursion, expect more AI-designed drug candidates to enter or complete early clinical trials in Q4 this year.

Senolytic Therapy Combined with Immune Checkpoint Inhibitors

  • Predicted Timeline: November-December 2026
  • Prediction Probability: 55%
  • Prediction Basis: Today’s news that PD-L2 blockade can clear senescent cells suggests immune checkpoints are directly related to senescent cell accumulation. Considering successful experience with PD-1/PD-L1 inhibitors in cancer immunotherapy and limitations of existing senolytic drugs (like dasatinib + quercetin), expect research teams or companies to announce preclinical or early clinical studies of combination therapies.

Biological Age Clocks Move from Research Tools to Clinical Diagnostic Standards

  • Predicted Timeline: Q1 2027
  • Prediction Probability: 60%
  • Prediction Basis: Today’s news that rentosertib clinical trial used 6 protein clocks to assess biological age + Harvard Gladyshev team proposing “incorporating aging biomarkers into routine clinical trials.” With standardization and cost reduction of proteomic and epigenetic clocks, expect FDA or EMA to release draft guidance on biological age clocks as clinical endpoints within next 3-6 months.
09-21-Daily09-19-日报